OncoSil Medical LtdASX: OSL

OncoSil submits US Reimbursement Application (Updated)

Sep 1, 2026 at 9:33 PM EDT · Issued by OncoSil Medical Ltd via ASX

Filed with ASX · Sep 1, 2026 at 9:33 PM EDT

On 6ix: 6ix.com/news/oncosil-submits-us-reimbursement-application-updated

ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113 AUSTRALIA TELEPHONE +61 2 8935 9629 WEB www.oncosil.com 1 ASX Announcement 2 September 2026 Clarification OncoSil Submits CMS Application for Transitional...

View Attachment

6ix hasn’t read this filing yet.

OncoSil Medical Ltd on 6ix

Earlier from OncoSil Medical

OncoSil submits US Reimbursement ApplicationSep 1
Appendix 4G and Corporate Governance StatementAug 28
Appendix 4E and Annual ReportAug 28
Change in substantial holdingAug 21
Change in substantial shareholding for OSLAug 19

Later from OncoSil Medical

Proposed issue of securities - OSLSep 7
OSL Secures $5.6 million from Major Institutional InvestorsSep 7
100th Patient Treated with OncoSil device in SpainSep 7
Australian Manufacturing Facility Achieves ISO 13485Sep 8
Application for quotation of securities - OSLSep 9

All OncoSil Medical news releases

Follow OncoSil Medical into a list and get an email when it puts out news.

Follow OncoSil Medical